Lipopolyplex Lipid Composition for Stable mRNA Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid-based drug delivery systems face challenges such as complex production methods, low drug encapsulation efficiency, poor stability in vivo, and reduced nucleic acid expression after lyophilization, necessitating the development of more efficient and stable lipid delivery systems with improved targeting capabilities.
Innovation Solution
A lipid composition comprising cationic lipids, phospholipids, steroids, and polyethylene glycol modified lipids, along with a cationic polymer, forms a lipopolyplex to encapsulate therapeutic or prophylactic agents like nucleic acids, enhancing stability and targeting efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liposome production method is used, then drug delivery system can be formed, but production process becomes complex and requires organic solvents
Solution Approach 1:
The invention extracts and eliminates the organic solvent step from the liposome production process. By using a water-based self-assembly method where lipids spontaneously form vesicles in aqueous solution containing the drug, the complex organic solvent extraction step is removed while still achieving effective drug encapsulation and delivery system formation.
Solution Approach 2:
The invention employs self-assembly of lipid molecules in aqueous solution to spontaneously form drug-loaded liposomes. The lipids automatically organize into vesicular structures encapsulating the drug without requiring complex external processing or organic solvents, enabling simplified one-step preparation while maintaining reliable drug delivery system formation.
2Reliability
If conventional liposome method is used, then drug delivery is achieved, but drug encapsulation efficiency is low
Solution Approach 1:
The invention optimizes parameters including lipid composition (using specific phospholipids, cholesterol, and PEG-lipid ratios), pH conditions, ionic strength, and temperature to enhance drug encapsulation efficiency. By carefully controlling these parameters during self-assembly, the system achieves high drug loading within liposomes while maintaining stable structure and effective delivery.
3Reliability
If unmodified LNP system is used, then nucleic acid delivery is achieved, but stability in vivo is poor and targeting effect is poor
Solution Approach 1:
The invention creates composite lipid nanoparticles incorporating multiple lipid components including ionizable cationic lipids, phospholipids, cholesterol, and PEG-modified lipids in optimized ratios. This composite structure provides enhanced stability in physiological environments, improved cellular uptake, and better nucleic acid delivery efficiency compared to single-component systems.
Solution Approach 2:
The invention introduces PEG-modified lipids at specific locations on the liposome surface to provide localized stabilization and extend circulation time in vivo. The PEG layer creates a protective hydrophilic corona that prevents opsonization and clearance by the reticuloendothelial system, thereby improving overall system stability without compromising nucleic acid delivery capability.
4Stability of the object's composition
If stabilizer such as N-(methoxy-poly(ethylene glycol)-oxycarbonyl)-distearoylphosphatidylethanolamine is added to improve stability, then stability is improved, but preparation process becomes complicated and costs increase
Solution Approach 1:
The invention uses PEG-modified lipids that perform multiple functions simultaneously: they provide steric stabilization to prevent aggregation, extend circulation time by reducing opsonization, and maintain structural integrity during lyophilization and storage. This multi-functional component eliminates the need for separate stabilizer additives, simplifying the formulation and preparation process while achieving comprehensive stability.
5Reliability
If existing lipid delivery system is used, then nucleic acid delivery is achieved, but expression amount of nucleic acid in vivo is relatively low and stability during lyophilization and storage is poor
Solution Approach 1:
The invention develops composite lipid formulations combining ionizable cationic lipids with specific phospholipids, cholesterol, and PEG-lipids in optimized ratios. This composite structure enhances nucleic acid complexation, protects against degradation, improves cellular uptake and endosomal escape, thereby significantly increasing in vivo expression levels while maintaining stability during lyophilization and storage.
Solution Approach 2:
The invention optimizes critical parameters including lipid composition ratios, particle size distribution, surface charge density, and formulation pH to maximize nucleic acid expression. By carefully controlling these parameters, the system achieves high transfection efficiency and robust in vivo expression while maintaining stability through freeze-drying and storage conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid composition achieves high encapsulation efficiency and stability, with improved in vivo expression of nucleic acids, particularly mRNA, and demonstrates strong immunogenicity and targeting capabilities.
Implementation Method 1
the cationic polymer and the therapeutic agent or the prophylactic agent are associated as a complex
Implementation Method 2
the cationic polymer and the therapeutic agent or the prophylactic agent are associated as a complex and co-encapsulated in the lipid to form a lipopolyplex
Data Source
AI summary
Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition including a therapeutic agent and/or a prophylactic agent such as an RNA can be used for delivering the therapeutic agent and/or the prophylactic agent to a mammalian cell or organ, so as to, for example, regulate polypeptide, protein, or gene expression.